title: Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
abstract: We conducted a retrospective analysis of 50 lymphoma patients (Hodgkin's disease and non-Hodgkin's lymphoma) who had an 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET) scan after at least two cycles of salvage chemotherapy and before autologous stem cell transplantation (ASCT) at our institution. The patients were categorized into FDG-PET negative (N = 32) and positive (N = 18) groups. The median follow-up after ASCT was 19 months (range: 3-59). In the FDG-PET-negative group, the median progression-free survival (PFS) was 19 months (range: 2-59) with 15 (54%) patients without progression at 12 months after ASCT. The median overall survival (OS) for this group was not reached. In the FDG-PET-positive group, the median PFS was 5 months (range: 1-19) with only one (7%) patient without progression at 12 months after ASCT. The median OS was 19 months (range: 1-34). In the FDG-PET-negative group, chemotherapy-resistant patients by CT-based criteria had a comparable outcome to those with chemotherapy-sensitive disease. A positive FDG-PET scan after salvage chemotherapy and prior ASCT indicates an extremely poor chance of durable response after ASCT.
authors.affiliation: Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA 19104, USA. jakub.svoboda@uphs.upenn.edu
authors.forename: J
authors.initials: J
authors.lastname: Svoboda
authors.forename: C
authors.initials: C
authors.lastname: Andreadis
authors.forename: R
authors.initials: R
authors.lastname: Elstrom
authors.forename: E A
authors.initials: EA
authors.lastname: Chong
authors.forename: L H
authors.initials: LH
authors.lastname: Downs
authors.forename: A
authors.initials: A
authors.lastname: Berkowitz
authors.forename: S M
authors.initials: SM
authors.lastname: Luger
authors.forename: D L
authors.initials: DL
authors.lastname: Porter
authors.forename: S
authors.initials: S
authors.lastname: Nasta
authors.forename: D
authors.initials: D
authors.lastname: Tsai
authors.forename: A W
authors.initials: AW
authors.lastname: Loren
authors.forename: D L
authors.initials: DL
authors.lastname: Siegel
authors.forename: E
authors.initials: E
authors.lastname: Glatstein
authors.forename: A
authors.initials: A
authors.lastname: Alavi
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
authors.forename: S J
authors.initials: SJ
authors.lastname: Schuster
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18